文献速递帕金森病与运动障碍

基于人群队列中咖啡摄入及诊断前咖啡因代谢物与帕金森病发病风险的关联

Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort.
PubMed 文献 · Neurology · 2024-03-21

在EPIC4PD前瞻性人群队列(184,024人)中,最高咖啡摄入量者较不饮用者帕金森病风险降低(HR 0.63,95%CI 0.46-0.88,p=0.006);巢式病例对照研究(351对)显示诊断前血浆咖啡因、副黄嘌呤和茶碱均与帕金森病风险呈负相关。

要点

  • 最高咖啡摄入量者较不饮用者帕金森病风险降低,HR 0.63(95%CI 0.46-0.88,p=0.006)。
  • 诊断前血浆咖啡因与帕金森病风险负相关,OR 0.80(95%CI 0.67-0.95,p=0.009)。
  • 诊断前血浆副黄嘌呤和茶碱与帕金森病风险负相关,OR分别为0.82和0.78。

核心结论

  • 本研究通过对诊断前数年血浆咖啡因及其代谢物的详细定量,表明咖啡对帕金森病的神经保护作用归因于咖啡因及其代谢物。

研究设计与样本

  • EPIC4PD研究为前瞻性人群队列,纳入6个欧洲国家共184,024人,帕金森病病例通过医疗记录识别并由神经科专家审核。
  • 在EPIC4PD队列内开展巢式病例对照研究,纳入351例新发帕金森病病例,按年龄、性别、研究中心和采血时空腹状态匹配351例对照。
  • 采用Cox比例风险模型估计咖啡摄入与帕金森病发病的风险比(HR)及95%CI,采用条件logistic回归模型估计咖啡因代谢物与帕金森病风险的比值比(OR)及95%CI。
  • 基线血浆咖啡因代谢物通过高分辨率质谱法定量。

主要发现

  • 在EPIC4PD队列中,多变量校正后最高咖啡摄入量者较不饮用者帕金森病发病HR为0.63(95%CI 0.46-0.88,p=0.006)。
  • 在巢式病例对照研究中,诊断前血浆咖啡因与帕金森病风险负相关,OR为0.80(95%CI 0.67-0.95,p=0.009)。
  • 诊断前血浆副黄嘌呤与帕金森病风险负相关,OR为0.82(95%CI 0.69-0.96,p=0.015)。
  • 诊断前血浆茶碱与帕金森病风险负相关,OR为0.78(95%CI 0.65-0.93,p=0.005)。
  • 校正吸烟和饮酒后,上述结果未发生实质性改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Inverse associations between caffeine intake and Parkinson disease (PD) have been frequently implicated in human studies. However, no studies have quantified biomarkers of caffeine intake years before PD onset and investigated whether and which caffeine metabolites are related to PD. METHODS: Associations between self-reported total coffee consumption and future PD risk were examined in the EPIC4PD study, a prospective population-based cohort including 6 European countries. Cases with PD were identified through medical records and reviewed by expert neurologists. Hazard ratios (HRs) and 95% CIs for coffee consumption and PD incidence were estimated using Cox proportional hazards models. A case-control study nested within the EPIC4PD was conducted, recruiting cases with incident PD and matching each case with a control by age, sex, study center, and fasting status at blood collection. Caffeine metabolites were quantified by high-resolution mass spectrometry in baseline collected plasma samples. Using conditional logistic regression models, odds ratios (ORs) and 95% CIs were estimated for caffeine metabolites and PD risk. RESULTS: In the EPIC4PD cohort (comprising 184,024 individuals), the multivariable-adjusted HR comparing the highest coffee intake with nonconsumers was 0.63 (95% CI 0.46-0.88, p = 0.006). In the nested case-control study, which included 351 cases with incident PD and 351 matched controls, prediagnostic caffeine and its primary metabolites, paraxanthine and theophylline, were inversely associated with PD risk. The ORs were 0.80 (95% CI 0.67-0.95, p = 0.009), 0.82 (95% CI 0.69-0.96, p = 0.015), and 0.78 (95% CI 0.65-0.93, p = 0.005), respectively. Adjusting for smoking and alcohol consumption did not substantially change these results. DISCUSSION: This study demonstrates that the neuroprotection of coffee on PD is attributed to caffeine and its metabolites by detailed quantification of plasma caffeine and its metabolites years before diagnosis.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Lai Y, Konijnenberg H, et al. Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort. Neurology. 2024. PMID: 38513162. doi:10.1212/WNL.0000000000209201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。